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Complement Factor I Promotes Progression of
Cutaneous Squamous Cell Carcinoma
Pilvi Riihila¨1,2, Liisa Nissinen1,2, Mehdi Farshchian1,2, Atte Kivisaari1,2, Risto Ala-aho1,2, Markku Kallajoki3,
Reidar Gre´nman4, Seppo Meri5, Sirkku Peltonen1, Juha Peltonen6 and Veli-Matti Ka¨ha¨ri1,2
The incidence of cutaneous squamous cell carcinoma (cSCC) is rising worldwide. We have examined the role of
complement components in the progression of cSCC. Analysis of cSCC cell lines (n¼ 8) and normal human
epidermal keratinocytes (n¼ 11) with whole transcriptome profiling (SOLiD), quantitative real-time reverse
transcriptase–PCR, and western blotting revealed marked overexpression of complement factor I (CFI) in cSCC
cells. Immunohistochemical analysis for CFI in vivo showed stronger tumor cell–specific labeling intensity in
invasive sporadic cSCCs (n¼ 83) and recessive dystrophic epidermolysis bullosa–associated cSCCs (n¼ 7) than in
cSCC in situ (n¼ 65), premalignant epidermal lesions (actinic keratoses, n¼ 64), benign epidermal papillomas
(seborrheic keratoses, n¼ 39), and normal skin (n¼ 9). The expression of CFI was higher in the aggressive Ha-ras-
transformed cell line (RT3) than in less tumorigenic HaCaT cell lines (HaCaT, A5, and II-4). The expression of CFI
by cSCC cells was upregulated by IFN-g and IL-1b. Knockdown of CFI expression inhibited proliferation and
migration of cSCC cells and resulted in inhibition of basal extracellular signal–regulated kinase (ERK) 1/2
activation. Knockdown of CFI expression potently inhibited growth of human cSCC xenograft tumors in vivo.
These results provide evidence for the role of CFI in the progression of cSCC and identify it as a potential
therapeutic target in this nonmelanoma skin cancer.
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INTRODUCTION
Nonmelanoma skin cancer is the most frequent cancer world-
wide, and its incidence is increasing (Rogers et al., 2010).
Approximately 20% of nonmelanoma skin cancers are
invasive cutaneous squamous cell carcinomas (cSCCs),
which have potential for recurrence and metastasis. It has
been estimated that the 5-year rate of metastasis for cSCC is
5% and that 20% of all skin cancer–related deaths are caused
by cSCC (Tufaro et al., 2011). The main risk factor for cSCC
is solar UVR, and the other important risk factors are
immunosuppression and chronic cutaneous ulcerations
(Kivisaari and Ka¨ha¨ri, 2013). Inflammation is an important
feature in the progression of premalignant lesions, i.e., actinic
keratoses (AKs) to invasive and metastatic cSCCs (Ratushny
et al., 2012).
The complement system has an important role in the acti-
vation of innate and acquired immunity. Complement is acti-
vated in a sequential manner via three distinct pathways––i.e.,
classical, lectin, or alternative pathway (Ricklin et al., 2010).
Activation of all three pathways leads to cleavage of C3 and C5
followed by the formation of membrane attack complex and
eventually target cell lysis. Activation of the complement
cascades is strictly controlled by soluble and cell surface
bound inhibitory molecules, which protect host cells from
complement-mediated destruction (Rutkowski et al., 2010a).
Complement factor I (CFI) is a soluble 88 kDa serine
protease, which is synthesized as a single polypeptide chain
and processed to glycosylated 50 kDa heavy and 38 kDa light
chains covalently linked by a disulfide bond (Goldberger
et al., 1984). CFI has an important role in the regulation of
complement activation, as it can inhibit activation of all three
pathways by cleaving activated C4b and C3b. CFI functions
with cofactors complement factor H (CFH) (Schulze et al.,
1993), complement receptor type 1 (CD35), C4b-binding
protein, and membrane cofactor protein (CD46) (Nilsson
et al., 2011). Normal human epidermal keratinocytes (NHEKs)
have previously been shown to express complement com-
ponents and inhibitors, including CFI (Dovezenski et al., 1992;
Timar et al., 2007a). In our recent study, we showed that
cSCCs overexpress CFH, the other inhibitor of the alternative
pathway (Riihila¨ et al., 2014).
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In this study, we have examined the role of CFI in the pro-
gression of cSCC. The results show marked overexpression of CFI
by cSCC cells in culture and by tumor cells in invasive cSCCs
in vivo. Moreover, the results show that CFI regulates prolifera-
tion and migration of cSCC cells and promotes growth of human
cSCC xenografts in vivo. These results provide evidence for the
role of CFI in the progression of cSCC and identify it as a poten-
tial therapeutic target in these cutaneous malignant tumors.
RESULTS
Overexpression of CFI in cSCC cells
The expression of complement system components in eight
cSCC cell lines (five primary and three metastatic) and in
primary human epidermal keratinocytes (NHEKs) from healthy
skin of five individuals was first determined by oligonucleotide
array–based (Affymetrix, Santa Clara, CA) expression profiling.
The expression of most complement components was
low in NHEKs, whereas significantly higher expression of
mRNAs for complement components C1rl, C1r, C1s, and C3
and complement inhibitors FHL-1, CFH/CFHR1, and CFI was
noted in cSCC cell lines (Figure 1a). To verify these find-
ings, next–generation–sequencing–based whole transcriptome
expression profiling (SOLiD) of NHEK and cSCC cell lines was
also performed. In general, the basal expression of mRNAs for
the majority of complement system components, with the
exception of C1r, C1s, and C3, was low in NHEK (Figure 1b).
In contrast, the levels for mRNAs of certain complement
components (C1r, C1s, C3, CFB, and CFD) and complement
inhibitors (CFH and CFI) were clearly elevated in cSCC cells as
compared with NHEKs (Figure 1b). In addition, the levels of
CFI mRNA were higher in metastatic cSCC cell lines than in
cell lines derived from primary cSCC. Analysis of CFI mRNA
levels in NHEKs and cSCC cells by quantitative real-time PCR
(qPCR) confirmed that the mean levels of CFI mRNA were
significantly increased in the cSCC cell lines, as compared
with NHEKs (Figure 1c).
Production of CFI by NHEKs and cSCCs was analyzed by
western blotting of the cell lysates. Specific bands correspond-
ing to CFI were noted most abundantly in cSCC cell cultures,
as compared with NHEKs (Figure 1d). The expression of CFI
by cSCC cells in vivo was also examined with immuno-
histochemistry (IHC) in xenograft tumors established with
human cSCC cells (UT-SCC-7) in severe combined immuno-
deficient (SCID) mice. The expression of CFI was detected
specifically in partially differentiated cSCC tumor cells in the
xenografts (Figure 1e).
Tumor cell–specific overexpression of CFI in cSCCs in vivo
To examine the expression of CFI during cSCC progression
in vivo, tissue microarrays consisting of sporadic UV-induced
invasive cSCCs (n¼83), cSCCs of patients with RDEBSCC
(n¼ 7), cSCCs in situ (cSCCIS, n¼ 65), and premalignant
lesions (AK, n¼64) were analyzed by IHC. Benign epidermal
papillomas, i.e., seborrheic keratoses (SKs, n¼39), and
normal skin (n¼ 9) were examined as controls.
The results showed marked tumor cell–specific staining for
CFI in cSCCs (Figure 2a–c) and RDEBSCC (Figure 2d). The
staining intensity was scored moderate (þ þ ) (Figure 2a) and
strong (þ þ þ ) (Figure 2b–d). In general, weaker staining
intensity for CFI was detected in cSCCIS (Figure 2h) and AK
(Figure 2g). Epidermal keratinocytes in SK (Figure 2f) and in
normal skin (Figure 2e) were mainly negative ( ) or weakly
positive (þ ) for CFI. Semiquantitative analysis of the immuno-
stainings revealed that the proportion of tumor sections
presenting strong staining (þ þ þ ) for CFI was significantly
higher in cSCC and RDEBSCC groups, as compared with
cSCCIS, AK, SK, and normal skin (Figure 2i).
Overexpression of CFI in Ha-ras-transformed tumorigenic
HaCaT cells
To further elucidate the role of CFI in the progression of cSCC,
the expression of CFI was determined in immortalized non-
tumorigenic keratinocyte–derived cell line (HaCaT) lacking
functional p53 and in three Ha-ras-transformed tumorigenic
HaCaT–derived cell lines (A5, II-4, and RT3, Mueller et al.,
2001). As shown in Figure 3a, the expression of CFI mRNA
was low in HaCaT, A5, and II-4 cells, whereas markedly
higher levels of CFI mRNA were noted in RT3, the most
aggressive ras-transformed tumorigenic HaCaT–derived cell
line. Similarly, the production of CFI protein determined by
western blotting was markedly upregulated in RT3 cells, as
compared with other HaCaT–derived cell lines (Figure 3b).
Regulation of CFI expression in cSCC and HaCaT cells by
cytokines and growth factors
To examine the regulation of CFI expression, HaCaT and Ha-
ras-transformed HaCaT cell lines with different basal CFI
expression were treated with cytokines and growth factors
present in the cSCC tumor microenvironment. Subsequent
analysis by qPCR showed that the low basal expression of CFI
mRNA was upregulated by IFN-g and IL-1b in HaCaT cells,
A5 and II-4 cells (Figure 3c), as well as in two primary cSCC
cell lines (UT-SCC-118 and -12A, Figure 3d). In contrast, in
RT3 cells the high basal expression of CFI was not further
upregulated by IL-1b, but downregulation of CFI mRNA levels
was noted in cultures treated with IFN-g and transforming
growth factor-b1 (Figure 3c).
CFI regulates cSCC cell proliferation and migration
To elucidate the functional role of CFI in cSCC cells, specific
small interfering RNA (siRNA) was utilized to knockdown CFI
expression (Figure 4a). A significant reduction in the number
of viable cells was detected at 48 and 72 hours time points in
CFI siRNA–transfected cSCC (UT-SCC-59A) cultures, as com-
pared with control siRNA–transfected cultures (Figure 4b).
Similar effect of CFI knockdown on proliferation was detected
with another cSCC cell line (UT-SCC-118) (Figure 4b). Potent
inhibition of ERK1/2 activation was also detected 72 hours
after CFI knockdown in UT-SCC-118 cells (Figure 4c). Further-
more, significant inhibition of migration of cSCC cells (UT-
SCC-59A and -118) was noted in CFI siRNA–transfected
cultures 16 and 24 hours after wounding (Figure 4d).
CFI promotes growth of cSCCs in vivo
Next, we examined the role of CFI in the growth of cSCC
in vivo in the xenograft model. Metastatic cSCC cell (UT-SCC-7)
P Riihila¨ et al.
Complement Factor I in Cutaneous Squamous Cell Carcinoma
580 Journal of Investigative Dermatology (2015), Volume 135
cultures were transfected with CFI and control siRNA and
incubated for 72 hours. Thereafter, the transfected cells
(5 106) were injected subcutaneously into the back of
SCID/SCID mice, and the growth of xenografts was followed
weekly. Interestingly, growth of cSCC xenografts was signifi-
cantly suppressed by knockdown of CFI expression, as
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Figure 1. Overexpression of complement factor I (CFI) in cutaneous squamous cell carcinoma (cSCC) cells. (a) Oligonucleotide array (Affymetrix)–based analysis
of normal human epidermal keratinocyte (NHEK) cultures (n¼ 5) and primary (Prim. cSCC; n¼ 5) and metastatic (Met. cSCC; n¼ 3) cSCC cell lines. The signal
values for NHEKs and cSCC cell lines are shown as a heat map. (*Po0.05, **Po0.01.) (b) Next-generation-sequencing (SOLiD) based transcriptome profiling of
NHEK cultures (n¼ 4) and primary (Prim. cSCC; n¼ 5) and metastatic (Met. cSCC; n¼3) cSCC cell lines. The signal values of NHEKs and cSCC cell lines are
presented as a heat map. (c) CFI mRNA levels of NHEK (n¼ 11) and cSCC cell lines (n¼7) were analyzed by quantitative real-time PCR and corrected for the
levels of b-actin mRNA in the same samples. Horizontal bars show the mean values for each group. (d) The expression of CFI in cell lysates of NHEKs and cSCC
cell lines was analyzed by western blotting under nonreducing conditions. Human serum was used as a positive control, and b-actin was used as a loading control.
Migration positions of molecular weight markers (in kDa) are shown on the left. (e) Human metastatic cSCC cells (UT-SCC-7; 5 106) were implanted
subcutaneously into the back of SCID/SCID mice. Xenografts were harvested after 40 days, and the expression of CFI was analyzed by immunohistochemistry. The
staining for CFI is specifically detected in tumor cell cytoplasm. Scale bar¼200mm. Statistical analysis (a, c) was performed with the Student’s t-test (a) or with the
Mann–Whitney two-way U-test (c).
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compared with control siRNA–transfected cSCC cells
(Figure 5a). Extended incubation of siRNA–transfected
UT-SCC-7 cultures in parallel showed that knockdown of
CFI mRNA persisted up to 15 days (data not shown).
Histological analysis of the xenografts harvested at day 18
after implantation revealed that tumors established with
CFI siRNA were less cellular than those in the control siRNA
group (Figure 5b). The Ki-67-positive proliferating cells were
detected close to the tumor margin in xenografts in both
groups (Figure 5b). However, the number of Ki-67-positive
cells was significantly lower in CFI siRNA xenografts than in
control siRNA xenografts (Figure 5b and c). To investigate the
effect of CFI knockdown on complement activation, cSCC
xenografts were labeled with IHC using an antibody against
C3b. Positive staining for C3b was detected on tumor cell
surface in cell clusters in the invasive edge of xenografts and
the number of positive cells, and the staining intensity was
stronger in CFI siRNA tumors, as a marker for C3b accumula-
tion. Moreover, IHC with antibody against proinflammatory
cytokine tumor necrosis factor-a (TNF-a) showed stronger
staining intensity and elevated number of positive cells in
CFI siRNA tumors, as compared with the control siRNA xeno-
grafts providing further evidence for complement activation.
DISCUSSION
The complement system is an integral part of host defense. It
can be activated via classical, lectin, or the alternative path-
way (Zipfel and Skerka, 2009). Of these, the classical pathway
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Figure 2. Expression of complement factor I (CFI) by tumor cells in cutaneous squamous cell carcinoma (cSCC). (a–h) Complement factor I (CFI) antibody was
used to stain sections of tissue microarray blocks containing cSCC (n¼ 83), recessive dystrophic epidermolysis bullosa (RDEBSCC; n¼ 7), cSCCIS (cSCC in situ,
Bowen’s disease; n¼ 65), premalignant lesions (actinic keratosis, AK; n¼ 64), benign epidermal papillomas (seborrheic keratosis, SK; n¼ 39), and normal
skin (n¼9). Moderate (a) or strong (b, c) cytoplasmic staining for CFI is detected in cSCC cells. (d) Strong cytoplasmic staining for CFI was also detected in tumor
cells in cSCC associated with RDEBSCC. Staining for CFI was absent in normal skin (e), SK (f), or AK (g) and weak in most cSCCIS (h) sections. Scale bars¼ 200mm.
(i) Semiquantative analysis of CFI staining in normal skin, SK, AK, cSCCIS, cSCC, and RDEBSCC tissue sections. Tumor cell–specific immunostaining for CFI was
scored as negative ( ), weak (þ ), moderate (þ þ ), and strong (þ þ þ ). The percentage of tumors with strong tumor cell–specific staining in cSCCs is
significantly higher than in normal skin, SK, AK, or cSCCIS sections (all Po0.001; the w2-test).
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is activated by antibodies and the lectin pathway by contact
with carbohydrates on microbial surfaces, whereas the
alternative pathway is continuously and spontaneously
activated. Activation of all pathways takes place in a
sequential manner, and this process is strictly controlled by
soluble and membrane bound inhibitors, which protect cells
in host tissues from damage (Zipfel and Skerka, 2009). CFI is a
complement inhibitor, which together with its cofactors has an
important role in regulating the activation of all three
pathways. CFI is a serine protease with a highly restricted
substrate specificity. It cleaves the a’-chain of activated C3b
with cofactors CFH, complement receptor 1 (CD35), and
membrane cofactor protein (CD46) (Nilsson et al., 2011). CFI
also inactivates C4b by cleavage of the a’-chain with the
cofactor C4b-binding protein, membrane cofactor protein, or
complement receptor 1. Furthermore, C4b-binding protein
can also act as a cofactor for inactivation of C3b (Nagasawa
and Stroud, 1977). CFI is synthesized mostly in the liver, and it
is secreted as a single 88 kDa protein. This is then cleaved by
furin to yield the mature proteolytically active CFI, which
consists of disulfide-linked heavy chain (50 kDa) and light
chain (38 kDa) found in serum. CFI has no endogenous
inhibitor, but its activity in vivo is regulated by the supply of
substrates (Nilsson et al., 2011). CFI is also produced by
keratinocytes (Timar et al., 2007b), skin fibroblasts (Vyse et al.,
1996), myoblasts (Schlaf et al., 2001), monocytes (Whaley,
1980), and endothelial cells (Julen et al., 1992).
The results of the present study show that tumor cells of
cSCCs produce CFI in culture and in vivo. The expression of
the mRNAs for CFI as well as production of CFI at the protein
level was elevated in most cSCC cell lines studied, whereas
the basal expression of CFI in NHEKs was low or negative.
IHC analysis of human cSCC xenograft tissue showed that
CFI was expressed by cSCC tumor cells in vivo. Further
investigation of CFI expression in vivo was carried out by
IHC analysis of tissue microarrays consisting of a large panel
of cSCCs, cSCCIS, AK, SK, and normal skin. Results of IHC
analysis revealed that CFI was specifically expressed by tumor
cells in cSCCs. In addition, the IHC analysis of RDEBSCCs,
an aggressive form of cSCC, revealed strong tumor cell–
associated CFI staining. Interestingly, strong or moderate
cytoplasmic CFI staining was detected in the majority of the
cSCC tumors, whereas no CFI-negative tumors were noted in
cSCC or RDEBSCC groups. CFI staining was clearly stronger in
cSCC tumor sections than in cSCCIS and AK, indicating that
the expression is induced at the invasive stage of the cSCC
progression. In contrast, staining for CFI was negative or weak
in the majority of normal skin and in benign epidermal
papillomas (SK). On the basis of these observations, we
propose CFI as a biological marker for the progression of
cSCC.
Analysis of Ha-ras-transformed HaCaT cells representing
different stages of cSCC progression (Mueller et al., 2001)
showed that basal CFI expression was low in parental HaCaT
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cells and in the benign tumorigenic Ha-ras-transformed cell
line (A5) and in the low tumorigenic cell line (II-4) but
markedly higher in the invasive tumorigenic Ha-ras-
transformed HaCaT cell line (RT3). These results indicate
that inactivation of p53 and activation of ras signaling are
not alone sufficient for induction of basal CFI expression, but
additional genomic alterations are required. Our results also
show that CFI expression in cSCC cells with low basal
expression is susceptible to stimulation by IL-1b, IFN-g, and
transforming growth factor-b1. These results are in accordance
with previous observation showing that inflammatory
cytokines, e.g., IFN-g, upregulate expression of CFI by
keratinocytes (Timar et al., 2007b). However, it appears that
in the Ha-ras-transformed HaCaT cell line (RT3) with high
basal expression of CFI, the expression is not further
upregulated by these cytokines and growth factors.
We have recently reported that the expression of certain
complement components and inhibitors is elevated in cSCC
cells, as compared with keratinocytes (Riihila¨ et al., 2014).
These observations are supported by the results of the present
study obtained using next-generation-sequencing based
expression profiling. Overexpression of C3, CFB, CFH, and
CFI was noted in cSCC cell lines, as compared with NHEK.
These findings suggest that cSCC cells can produce and
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Figure 4. Complement factor I (CFI) promotes proliferation and migration of cutaneous squamous cell carcinoma (cSCC) cells. (a) Primary cSCC cell cultures
(UT-SCC-59A) were transfected in parallel with CFI small interfering RNA (siRNA) and control siRNA (120 nM). The level of CFI mRNA was measured with
quantitative real-time PCR 72 hours after transfection and corrected for the levels of GAPDH mRNA in the same samples (left panel). The cell lysates of control and
CFI siRNA–transfected UT-SCC-59A cells were analyzed by western blotting at 48 hours time point under reducing conditions. The levels of CFI were quantitated
by densitometry and corrected for the levels of b-actin in the same samples (right panel). (b) The number of viable cells (UT-SCC-59A and -118) was determined
24, 48, and 72 hours after siRNA transfection using the WST-1 assay (n¼ 5–8 parallel wells; ***Po0.001, Student’s t-test). (c) The levels of phosphorylated
extracellular signal-regulated kinase (ERK)1/2 (p-ERK1/2), total ERK1/2, phosphorylated p38 (p-p38), and total p38 were analyzed by western blotting 72 hours after
siRNA transfection. p-ERK1/2 and p-p38 blots were analyzed densitometrically and corrected for the levels of total ERK1/2 and p38, respectively (below the blots).
(d) Primary cSCC cells (UT-SCC-59A and -118) were transfected with CFI and control siRNA and incubated for 48 hours. The cultures were then treated with 1 mM
hydroxyurea for 6 hours to inhibit cell division. A scratch was generated in the cell monolayer by pipet tip, and incubation was continued in DMEM with 1% fetal
calf serum and 0.5 mM hydroxyurea for 24 hours. Representative images of the experiment are shown at time points 0, 16, and 24 hours (upper panel). The
quantitation of relative migration rates is shown in lower panel (n¼ 3; Po0.001, Mann–Whitney U-test).
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activate components of the complement system, and this way
may promote inflammation in the tumor microenvironment. It
is likely, that tumor cells can utilize complement inhibitors for
immune evasion (Gorter and Meri, 1999). Expression of CFI by
tumor cells has been shown in glioma (Gasque et al., 1992),
non-small-cell lung cancer (Okroj et al., 2008), and
rhabdomyosarcoma (Legoedec et al., 1995). The results of
the present study, together with our previous observations
(Riihila¨ et al., 2014), provide evidence that cSCC cells can
protect themselves from complement-mediated cell killing by
producing complement inhibitors CFH and CFI. This notion is
supported by the observation that CFI knockdown results in
accumulation of C3b in the cell surface of tumor cells in cSCC
xenografts (Figure 5b).
The results of this study also provide evidence for two, to
our knowledge previously unreported, functions of CFI, i.e.,
regulation of cell proliferation and migration, which are
especially relevant in cancer growth and invasion.
Interestingly, potent inhibition of ERK1/2 activation in cSCC
cells in culture was noted following knockdown of CFI
expression. Similar effect has been reported previously in
cultured cSCC cells with CFH, another important soluble
inhibitor of complement and cofactor for CFI (Riihila¨ et al.,
2014). Together these observations provide evidence that
inhibition of the alternative pathway of complement can
regulate proliferation and survival of malignant cells. These
observations are also supported by our results showing that
knockdown of CFI in cSCC cells results in significant
inhibition of cSCC cell implantation and subsequent tumor
growth in vivo in the xenograft model in SCID mice. The exact
mechanism for the mitogenic effect of the CFI is not known,
but it may involve generation of a mitogenic fragment from C3
by CFH and CFI (Vetvica et al., 1993). Our results also show
that CFI knockdown results in accumulation of C3b on the
tumor cell surface in cSCC xenografts. Further evidence for
complement activation is also provided by stimulation of TNF-a
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Figure 5. Complement factor I (CFI) promotes growth of cutaneous squamous cell carcinoma (cSCC) in vivo. (a) Human metastatic cSCC cells
(UT-SCC-7) were transfected with control and CFI small interfering RNAs (siRNAs) for 72 hours. Cells (5106) were then implanted subcutaneously into the back
of SCID/SCID mice, and the growth of tumors was measured as indicated. *Po0.05, ***Po0.001, Student’s t-test (n¼ 8). (b) Xenografts were harvested after 18
days, and the histology was analyzed in tumor sections stained with hematoxylin and eosin (HE). Ki-67, C3b, and tumor necrosis factor-a (TNF-a) were detected in
xenografts by immunohistochemistry, and Mayer’s hematoxylin was used as counterstain. The proliferating cells were identified by Ki-67. The staining for C3b in
CFI siRNA group was stronger than in the control group, and the staining was specifically noted on cell surface and in tumor cell cytoplasm in the invasive edge of
the tumor. Specific staining for TNF-a was detected in the cytoplasm of cSCC tumor cells. The staining intensity for TNF-a was more abundant, and there were
positively stained cells in wider areas in CFI siRNA xenografts compared with control siRNA xenografts. Representative stainings from each group are shown.
(c) The relative number of Ki-67-positive cells was determined by counting 300–500 cells at  20 magnification in all tumor sections using digital imaging.
Statistical significance between control and CFI siRNA groups was determined by the Mann–Whitney U-test (n¼ 6). Scale bars¼ 200mm.
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production in xenografts in response to CFI knockdown. It is
therefore possible that complement-mediated cell destruction is
at least in part responsible for reduced growth of CFI siRNA
xenografts. These results are in accordance with previous
observations showing that, although the activation of the
classical pathway of complement is defective in SCID mice
due to lack of immunoglobulins, the activation of the alternative
pathway examined in this study is intact (Reca et al., 2007).
However, it is also possible that CFI as a serine protease may
have additional functions on tumor growth beyond regulation of
complement activation (Rutkowski et al., 2010b).
Taken together, our results demonstrate tumor cell–
associated overexpression of the important inhibitor of the
complement system, CFI in cSCCs. These results provide
evidence that this complement inhibitor has an important role
in the progression of cSCCs, possibly by allowing tumor cells
escape from complement attack. In addition, our results show
that CFI promotes cSCC cell proliferation and migration and
promotes cSCC growth in vivo. In conclusion, these results
suggest that CFI has an important role in the progression of
cSCC and identify it as a therapeutic target in this form of
nonmelanoma skin cancer.
MATERIALS AND METHODS
Ethical issues
The use of archival tissue specimens and collection of normal skin
and cSCC tissues was approved by the Ethics Committee of the
Hospital District of Southwest Finland. The study was carried out
according to ‘the Declaration of Helsinki Principles’ with the
approval of Turku University Hospital. Written informed consent of
all patients was obtained before surgery.
Cell cultures
Primary human epidermal keratinocytes (NHEK-PC) were acquired
from PromoCell (Heidelberg, Germany). In addition, NHEKs were
established from skin samples obtained from mammoplasty (n¼ 11).
Human cSCC cell lines (n¼ 8) were established from the cSCCs at the
time of operation (Farshchian et al., 2011). Five of these were derived
from primary cSCCs (UT-SCC-12A, -91, -105, -111, and -118) and
three from metastases (UT-SCC-7, -59A, and -115). The sponta-
neously immortalized non-tumorigenic human keratinocyte–derived
cell line (HaCaT, Boukamp et al., 1988) and three Ha-ras-transformed
tumorigenic HaCaT cell lines (A5, II-4, and RT3, Boukamp et al.,
1990) were kindly provided by Dr Norbert Fusenig (Deutsche
Krebsforschungszentrum, Heidelberg, Germany). A5 cells form
benign, II-4 cells low-grade malignant and RT3 cells high-grade
malignant tumors in vivo in nude mice (Mueller et al., 2001). Cells
were cultured as previously described (Riihila¨ et al., 2014). For
cytokine and growth factor treatment, UT-SCC-118, -12A, and
HaCaT cell lines were maintained in serum-free DMEM for 24 hours
and then treated with IL-1b (10 ngml 1; Calbiochem, La Jolla, CA),
IFN-g (100 U ml 1; Promega Corporation, Madison, WI), or
transforming growth factor-b1 (5 ng ml 1; Sigma Aldrich, St Louis,
MO) for 24 hours.
Gene expression profiling
The expression of complement system components in NHEKs
(n¼ 5) and in eight cSCC cell lines (five primary and three metastatic)
was determined with Affymetrix Human Genome U133
Plus 2.0 array (Affymetrix) as previously described (Riihila¨ et al.,
2014). Whole transcriptome libraries of NHEKs (n¼ 4) and cSCC cell
lines (n¼ 8) were prepared with the SOLiD Whole Transcriptome
Analysis Kit (Applied Biosystems, Foster City, CA) at Finnish
Microarray and Sequencing Centre, Turku Center for Biotechnology,
Turku, Finland. The samples were processed with the SOLiD
3Plus instrument (35 bp read length, NHEKs and SCCs). The
colorspace reads were aligned against the human reference genome
(GRCh37 assembly for NHEKs and SCCs) using the standard whole
transcriptome pipeline and the colorspace alignment tool (Applied
Biosystems). The quantile-to-quantile adjustment (R/Bioconductor
package edgR) was used to normalize the data (Robinson
et al., 2010).
qPCR
Total RNA was isolated from cultured cells using the RNeasy Mini Kit
(Qiagen, Chatsworth, CA). cDNA was synthesized using 1mg of total
RNA, treated with RQ1 DNase (M610A, Promega ), random primers
(C118A, Promega), M-MLV reverse transcriptase (M531A, Promega),
and RNase H minus polymerase (M368B, Promega). qPCR analysis of
cDNA samples was performed with specific primers and fluorescent
probes, as previously described (Stokes et al., 2010). For CFI, the
following primers and probe were used:
Forward primer 50-CTCAGCAGAGACAAAGAC-30
Reverse primer 50-GTGGAAGCACAGAAATAAC-30
CFI Probe 50-CCCGAACACCTCCAACATGAAGC-30
Primers and probes for b-actin and GAPDH have been described
previously (Riihila¨ et al., 2014). Samples were analyzed in duplicate.
The range of the threshold cycle values was o5% of the mean in
each measurement. The results for CFI mRNA were corrected for
expression of b-actin or GAPDH mRNA in the same samples.
Western blot analysis
The production of CFI by NHEKs, cSCC, and HaCaT cell lines was
determined by western blotting of cell lysates both under reducing
and nonreducing conditions using mouse monoclonal anti-CFI
antibody (1:500; clone OX-21, Novus Biologicals, Littleton, CO).
Equal protein loading was confirmed with mouse monoclonal anti-b-
actin antibody (A 1978; Sigma Aldrich; Riihila¨ et al., 2014).
Tissue samples and immunohistochemistry
Altogether, 260 formalin-fixed paraffin-embedded tissue samples
were accessed from the archives of the Department of Pathology,
Turku University Hospital. These included sporadic UV-induced
cSCC (n¼ 83; mean age 79 years, range 45–102 years), cSCCIS
(Bowen’s disease; n¼ 65; mean age 79 years, range 59–95 years), AK
(n¼ 64; mean age 78 years, range 58–95 years), seborrheic keratoses
(n¼ 39; mean age 66 years, range 26–95 years), and normal skin
(n¼ 9). In addition, RDEBSCCs (n¼ 7; mean age 33 years, range 12–
56 years) were used (Kivisaari et al., 2008). Tissue microarray blocks
were generated of these samples as described (Kononen et al., 1998).
The sections were stained with mouse monoclonal anti-CFI antibody
(clone OX-21, Novus Biologicals), diluted (1:150) in phosphate-
buffered saline containing 1.5% horse serum, as previously
described (Kivisaari et al., 2008; Farshchian et al., 2011). For
negative control stainings, the primary antibody was replaced with
phosphate-buffered saline. The intensity of cytoplasmic staining was
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scored as negative ( ), weak (þ ), moderate (þ þ ), or strong
(þ þ þ ) by two independent observers (PR and MK).
siRNA knockdown of CFI expression
For siRNA knockdown of CFI, cSCC cells were grown to 50%
confluency and transfected with siRNA targeting CFI mRNA or with
negative control siRNA (120 nM; Qiagen, Hilden, Germany) using
siLentFect Lipid Reagent (Bio-Rad Laboratories, Hercules, CA), as
previously described (Kivisaari et al., 2010). Cells were harvested 24,
48, and 72 hours or 6, 10, and 15 days after transfection. The levels of
CFI mRNA were determined by qPCR and CFI protein levels by
western blotting.
Cell proliferation
cSCC cells were transfected with CFI siRNA or with negative control
siRNA (120 nM). Twenty-four hours after transfections, cells
(1.0 104 cells per well) were seeded on 96-well plates. The number
of viable cells was determined with WST-1 cell proliferation reagent
(Roche Diagnostics, Mannheim, Germany). In each time point, 5–8
parallel wells were analyzed with two cSCC cell lines (UT-SCC-59A
and -118). Activation of ERK1/2 and p38 was determined by western
blotting of the cell lysates with specific antibodies for phospho-ERK1/
2 and phospho-p38 and for total ERK1/2 and p38 (all from Cell
Signaling Technology, Beverly, MA).
Cell migration
Cells were transfected with CFI siRNA or negative control siRNA
(120 nM) and incubated for 48 hours. To inhibit cell division, cells
were then treated with 1 mM hydroxyurea (Sigma Aldrich) in DMEM
with 1% fetal calf serum for 6 hours. A scratch was created with a
pipet tip in the cell monolayer, and incubation was continued in
DMEM with 10% fetal calf serum and 0.5 mM hydroxyurea for
24 hours. Migration was analyzed with Olympus IX70 inverted
microscope (Olympus Optical, Tokyo, Japan), and the cell-free area
was measured in four areas, in one well with ImageJ software
(Schneider et al., 2012) and in three parallel wells with two cSCC
cell lines (UT-SCC-59A and -118).
Human cSCC xenografts
Establishment of human cSCC xenografts was performed using a
highly tumorigenic cSCC cell line (UT-SCC-7), as described pre-
viously (Ala-aho et al., 2004; Leivonen et al., 2006; Junttila et al.,
2007). All experiments with mice were carried out with permission of
the animal test review board of the Southern Finland according to
institutional guidelines. UT-SCC-7 cells were transfected with CFI or
control siRNA and incubated for 72 hours. Subsequently, 5 106
cells in 100 ml of phosphate-buffered saline were injected subcuta-
neously into the back of SCID female mice (CB17/Icr-Prkdcscid/
IcrIcoCrl) (n¼ 8 for each group) (Charles River Laboratories,
Wilmington, MA). The size of tumors was measured once a week,
and their volume calculated as p4/3((lengthþwidth)/4)3 (Watt et al.,
2011). In the end, tumors were harvested and processed for
histological analysis and IHC, as previously described (Junttila
et al., 2007). Proliferating cells were detected by Ki-67
immunostaining using monoclonal antibody for human Ki-67 (MIB-
1; DAKO, Glostrup, Denmark) with Mayer’s hematoxylin as
counterstain. The relative number of Ki-67-positive cells was
determined by counting 300–500 cells at 20 magnification from
all sections using ImageJ Software. Polyclonal goat anti-C3 antibody,
which specifically detects C3b (Calbiochem, La Jolla, CA), and rabbit
polyclonal antibody against human TNF-a (H-156; Santa Cruz
Biotechnology, Dallas, TX) were used for immunostaining of tumors
with Mayer’s hematoxylin as counterstain.
Statistical analysis
The statistical analyses were performed using the SPSS software (IBM
SPSS, Armonk, NY). The significance of differences between sample
groups for oligonucleotide array, whole transcription profiling, qPCR,
cell proliferation and cell migration assays, and xenograft analysis
was determined with the Mann–Whitney U-test or Student’s t-test, as
indicated. Comparison of IHC staining intensity was performed with
the w2-test.
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